Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?

Eddy Fan, Jeremy R Beitler, Laurent Brochard, Carolyn S Calfee, Niall D Ferguson, Arthur S Slutsky, Daniel Brodie

The COVID-19 pandemic has seen a surge of patients with acute respiratory distress syndrome (ARDS) in intensive care units across the globe. As experience of managing patients with COVID-19-associated ARDS has grown, so too have efforts to classify patients according to respiratory system mechanics, with a view to optimising ventilatory management. Personalised lung-protective mechanical ventilation reduces mortality and has become the mainstay in treatment of ARDS. In this Viewpoint, we address ventilatory strategies in the context of recent discussions on phenotypic heterogeneity in patients with COVID-19-associated ARDS. Although early reports suggested that COVID-19-associated ARDS has distinctive features that set it apart from historical ARDS, emerging evidence indicates that the respiratory system mechanics of patients with ARDS, with or without COVID-19, are broadly similar. In the absence of evidence to support a shift away from the current paradigm of ventilatory management, we strongly recommend adherence to evidence-based management, informed by bedside physiology, as resources permit.

Introduction

The global experience of managing patients with COVID-19-associated acute respiratory distress syndrome (ARDS) is rapidly expanding, along with an increasing number of reports on respiratory system mechanics and ventilatory management. Over the past two decades, the heterogeneity of ARDS has increasingly been recognised, and efforts have been made to describe subgroups of patients with different clinical and biological characteristics, clinical outcomes, and treatment responses. As hospitals have faced a surge of patients with COVID-19 and health-care professionals have worked under enormous pressure, often with limited resources, to save the lives of patients with ARDS, observations of heterogeneity in both the clinical features and clinical course of COVID-19-associated ARDS have led to proposals for different management strategies on the basis of described phenotypes. Phenotypic heterogeneity is an important concept, but there is a risk of overinterpretation or inappropriate application of these principles, which can have detrimental implications for outcomes of ventilatory management. Given the importance of lung-protective mechanical ventilation in ARDS, in this Viewpoint we address ventilatory strategies in the context of recent reports that discussed phenotypic heterogeneity in patients with COVID-19-associated ARDS. Without a strong evidence base to guide a shift from the current paradigm of patient management, we strongly recommend adherence to evidence-based management, informed by bedside physiology, and supported by current data.

Description of phenotypes in COVID-19-associated ARDS

In a case series of 16 mechanically ventilated patients with COVID-19,Gattinoni and colleagues described severe hypoxaemia despite relatively normal lung compliance—an unusual finding in patients with severe ARDS. In eight patients, blood gases and CT scans revealed a large shunt fraction despite relatively small amounts of gasless tissue, suggesting hyperperfusion of poorly ventilated lung regions. Because the lungs appeared relatively open, they recommended a lower positive end-expiratory pressure (PEEP) strategy, as well as avoidance of prone positioning, especially because of potential limitations in human resources during the pandemic.

In a second report, the authors highlighted the non-uniformity of patients with COVID-19-associated ARDS and proposed the existence of two primary phenotypes: type L (low values of elastance, pulmonary ventilation/perfusion ratio, lung weight, and recruitability) and type H (high values of elastance, right-to-left shunt, lung weight, and recruitability), with the latter being more consistent with what they describe as typical severe ARDS. Gattinoni and colleagues proposed that most patients present early with type L, and that some transition to type H, potentially

Key messages

- During an outbreak such as the COVID-19 pandemic, it is important to balance the rapidly evolving and initially low-level evidence—largely case series, case reports, and anecdotes—with the scientific rigour needed to support any necessary shifts in the current paradigm of patient management
- The notion that acute respiratory distress syndrome (ARDS) is a heterogeneous syndrome is a ubiquitous finding as old as the concept of ARDS itself, contributing substantially to the complexity of its management; heterogeneity is most relevant when linked to differential treatment effects, which have been shown to improve outcomes
- Reports of phenotypic heterogeneity in patients with COVID-19-associated ARDS, although interesting, could easily be overinterpreted or inappropriately applied in the intensive care unit, potentially leading to detrimental ventilatory management strategies in these patients
- Large observational studies suggest that patients with COVID-19-associated ARDS have similar respiratory system mechanics to patients with ARDS from other causes and that, for most patients, COVID-19-associated ARDS is, in the end, ARDS
- We strongly recommend adherence to evidence-based management, informed by bedside physiology, and supported by outcome data; this approach includes lung-protective mechanical ventilation, individualised positive end-expiratory pressure, prone positioning, and venovenous extracorporeal membrane oxygenation—as suggested by international guidelines for ARDS, and as resources permit
due to the synergistic effects of worsening COVID-19 pneumonia and patient self-inflicted lung injury.13 Therefore, the authors10 advocated early endotracheal intubation in patients with excessive respiratory efforts, and stated that once “…deeply sedated, the Type L patients, if hypercapnic, can be ventilated with volumes greater than 6 mL/kg (up to 8–9 mL/kg) predicted body weight, as the high compliance results in tolerable strain without the risk of VILI [ventilator-induced lung injury].” A third report on this subject re-emphasised these key points.11

We are at an early stage in understanding the heterogeneity of COVID-19-associated ARDS (eg, pathophysiological features, clinical course, biomarkers, and phenotypes based on respiratory mechanics). The rigorous identification of phenotypes could ultimately help to guide the management of patients who are critically ill with COVID-19. At present, we argue that an evidence-based approach informed by decades of research in ARDS is needed.

**Recommendations for management of COVID-19-associated ARDS**

The notion that ARDS is a heterogeneous syndrome—presenting with variable mechanical and gas exchange disturbances—is an important but ubiquitous finding and as old as the concept of ARDS itself. This clinical and biological heterogeneity contributes substantially to the complexity of managing the syndrome. Heterogeneity is clinically relevant when linked to differential treatment effects. For example, hyperinflammatory versus hypo-inflammatory subphenotypes might respond differently to PEEP levels and fluid management.14 Identifying recruitability with a simple bedside technique could help to tailor ventilatory management in patients with ARDS, including those with COVID-19.18 However, the application of such a tailored physiological approach does not necessarily equate to improved outcomes with that treatment. Similarly, an atypical presentation of ARDS does not necessarily mean that the patient will respond differently to a typical treatment regimen.3

In this context, we propose recommendations for the treatment of COVID-19-associated ARDS, from both a practical and theoretical perspective. First, lung protection with volume-limited and pressure-limited ventilation was initially shown to be effective in a heterogeneous ARDS population with a wide range of physiological parameters, including static compliance, plateau pressure, and the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen. Similar to patients with COVID-19 with the proposed L phenotype, patients with mild ARDS typically have higher respiratory system compliance than do those with more severe ARDS. Some data suggest that a lung-protective strategy can be beneficial even in patients with relatively low plateau pressures.39 Moreover, a number of studies have shown that using lung-protective ventilation in patients who have relatively normal lungs is associated with fewer pulmonary complications, including decreased progression to ARDS, and improved clinical outcomes.39 Patients with the robust inflammatory response common in COVID-19 are probably biologically primed to develop ventilation-induced lung injury.20 The respiratory system mechanics and risk of lung strain in these patients might worsen quickly, especially with the resumption of spontaneous efforts to breathe.22 Therefore, liberalising tidal volumes in these patients might be associated with worse outcomes, even if they do not have what might be regarded as typical ARDS.

|                  | Italy9 | Seattle, WA, USA10 | Italy11 | Boston, MA, USA1 | Amsterdam12 | New York City, NY, USA13 | New York City, NY, USA14 |
|------------------|--------|--------------------|---------|----------------|-------------|---------------------------|---------------------------|
| Number of patients | 16     | 24                 | 1300    | 66             | 38          | 257                       | 267                       |
| Respiratory support |       |                    |         |                |             |                           |                           |
| Invasive mechanical ventilation | 16 (100%) | 18 (75%)          | 1150 (88%) | 66 (100%) | 38 (100%) | 203 (79%) | 267 (100%) |
| Non-invasive ventilation | 0      | 0                  | 137 (11%) | 1 (2%)       | 0           | 3 (1%)             | 51 (19%)             |
| HFNC             | 0      | 10 (42%)           | 0       | 1 (2%)       | 0           | 12 (5%)            | 0                         |
| PaO2/FiO2 ratio |        | 142 (94–177)     | 160 (114–220) | 182 (135–245) | 132 (48)† | 129 (80–203) | 103 (82–134) |
| Compliance, mL/cm H2O | 50 (14 3)† | 29 (25–36)        | ...      | 35 (30–43) | 49 (24)† | 26 (21–38) | 28 (23–38) |
| Plateau pressure, cm H2O | ...    | 25 (20–28)        | ...      | 21 (19–26) | 21 (7–23) | 27 (22–31) | 25 (21–29) |
| PEEP, cm H2O   | ...    | 14 (12–16)        | 10 (8–12) | 10 (9–12)   | 15 (12–18) | 10 (8–12)   |                           |
| Tidal volume, mL/kg PBW | ...    | ...               | ...      | ...         | ...        | ...          |                           |
| FIO2             | ...    | 90% (70–100)      | 70% (50–80) | ...       | ...         | 100% (80–100) | ...                       |
| Prone positioning | Not reported | 5/28 (28%)        | 240/875 (27%) | 31 (47%) | Not reported | 35 (17%) | 108 (40%) |
| ECMO             | Not reported | 5/498 (1%)        | 3 (5%)   | Not reported | 7 (3%)     | Not reported   |                           |

Data are n (%) or median (IQR), unless otherwise indicated. ECMO=extracorporeal membrane oxygenation. FiO2=fraction of inspired oxygen. HFNC=high-flow nasal cannula. PaO2=partial pressure of arterial oxygen. PBW=predicted body weight. PEEP=positive end-expiratory pressure. *Some patients received more than one type of respiratory support. †Mean (SD). ‡Denominator is 18 for the group that had invasive mechanical ventilation. §It is not explicitly stated in the manuscript why the denominators are different, although they might represent the group of patients for which these data were collected and available at the time of analysis.

Table 1: Selected ventilatory characteristics of critically ill patients with COVID-19
Gattinoni and colleagues recommended the use of tidal volumes greater than 6 mL/kg predicted bodyweight for patients with type L COVID-19-associated ARDS who develop hypercapnia. Because of the potential for greater ventilator-induced lung injury with higher tidal volumes, we suggest that clinicians first address common treatable causes of hypercapnia before resorting to the use of higher tidal volumes. These causes might include the following: inadequate respiratory rate; increased dead space from a heat and moisture exchange filter at the Y-connector, which might be used out of an abundance of caution to prevent cross-contamination, instead of a heated humidifier; or ventilators used without the circuit compliance compensation turned on, reducing the volumes delivered to patients. Metabolic attention to these details, before consideration of abnormal vascular components of dead space as a cause of hypercapnia, is strongly encouraged before increasing the tidal volume above 6 mL/kg predicted bodyweight.

Second, what level of hypercapnia is tolerable? Permitting hypercapnia with the use of lower tidal volumes might mitigate the initial risk of ventilator-induced lung injury and be well tolerated. But it is also associated with a number of detrimental effects such as: facilitating bacterial growth in the lung; inhibiting alveolar wound repair, reabsorption of alveolar fluid, and alveolar cell proliferation; and increasing pulmonary hypertension. Third, the proposed temporal evolution of the type L and type H subtypes, in contrast to previous reports in patients with ARDS, raises the important question of whether the proposed subtypes merely reflect the natural evolution of ARDS. This issue is particularly relevant in patients with COVID-19-associated ARDS who might have been intubated earlier in the disease course than is usually the case. Comparison of data between reports is difficult because the decision to intubate might have been made at distinctly different timepoints in the course of patients’ illness at different centres due to resource limitations. All of this raises the difficult question of the optimal point at which to intubate a given patient, because we know that the window can be narrow and that the consequences of intubating too early or too late could be substantial.

### Table 2: Clinical and physiological considerations in the management of patients with COVID-19-associated ARDS

| Considerations | Potential course of action |
|----------------|---------------------------|
| **Timing of intubation** | • No high-quality clinical trial evidence addressing optimal timing of intubation in ARDS is available<br>• Intubation might be beneficial in patients with high respiratory drive and at high risk of patient self-inflicted lung injury<br>• Non-invasive ventilation has been associated with worse outcomes when PaO2/FiO2 ratio <150 in ARDS<br>• Detrimental consequences of intubation and invasive ventilation (eg, related to sedation, paralysis, and endotracheal tube complications) might outweigh benefits, especially in patients with mild hypoxaemia and without high respiratory drive or work of breathing<br>• Consequences for other patients because of bed and ventilator shortages in the ICU should be considered | • Consider timely intubation as indicated by refractory hypoxaemia or hypercapnia, and by objective evidence of high work of breathing on clinical examination (eg, phasic [not tonic] contraction on palpation of sternomastoid) or by oesophageal manometry<br>• Lower tidal volume as needed to 4 mL/kg PBW to keep plateau pressure <30 cm H2O<br>• Liberalise tidal volume (up to 8 mL/kg PBW) in patients who are double triggering, or if inspiratory airway pressure decreases below PEEP, keeping plateau pressure <30 cm H2O<br>• Ideally, keep driving pressure <14 cm H2O |
Fourth, the question of what PEEP levels to use is more complex than the previous discussion on the management of tidal volume. Previous data already suggest that the same PEEP should not be applied to all patients with ARDS, individualisation is needed because the response to PEEP differs on the basis of individual respiratory mechanics. The seminal studies of Suter and colleagues and Dantzker and colleagues showed that PEEP can improve hypoxaemia while reducing tissue oxygen delivery. If, in fact, there is a subphenotype in which vascular derangement is the major mechanism for the hypoxaemia (eg, loss of pulmonary vasoconstriction, or pulmonary emboli or thrombi), then increasing PEEP might not improve hypoxaemia. Therefore, PEEP should be targeted to improve oxygen delivery while mitigating the risk of ventilator-induced lung injury and patient self-inflicted lung injury, depending on the clinical context. This titration remains complicated to achieve in patients with ARDS with or without COVID-19.

Evidence for phenotypes in COVID-19-associated ARDS

Nearly a third of patients in the reports byGattinoni and colleagues had severe (proposed type H) ARDS, consistent with previously reported patients with ARDS. In two reports of patients receiving mechanical ventilation for COVID-19-associated ARDS from New York City, NY, USA, the median respiratory system compliances were 28 mL/cm H₂O and 26 mL/cm H₂O, not unusual for patients with ARDS. Similar values of compliance were reported in two smaller studies from Seattle, WA, USA and Boston, MA, USA (median compliances of 29 mL/cm H₂O and 35 mL/cm H₂O, respectively; table 1). These data do not preclude the existence of subphenotypes with high respiratory system compliance. However, they do suggest that, on average, patients with COVID-19-associated ARDS probably have similar respiratory system mechanics to patients with ARDS from other causes and that, for most patients, COVID-19-associated ARDS is, in the end, ARDS. Viewing COVID-19-associated ARDS as a different entity suggests the need to abandon current treatment principles in favour of a new approach. Without robust evidence to the contrary, a new approach should not be considered because of risks of harm. Patients with moderate-to-severe COVID-19-associated ARDS should receive prone positioning and patients with severe ARDS might need venovenous extracorporeal membrane oxygenation, as indicated in international guidelines for ARDS, and as resources permit.

Conclusions and future directions

What does all of this mean for how we should ventilate patients with ARDS due to COVID-19? Table 2 outlines our recommendations to help set ventilatory strategy based on underlying pulmonary pathophysiology in patients with COVID-19. We suggest that the focus should be on using our existing ARDS ventilation evidence base to guide therapy, while adjusting as necessary based on individual patient-specific issues. For example, apparent heterogeneity might be due to the fact that there is a distinct underlying pathological process contributing to hypoxaemia in some patients, which requires non-ventilatory therapy (eg, increased prevalence of thromboembolic complications in COVID-19). Of course, if such a patient requires mechanical ventilation, it is not appropriate to use a ventilatory strategy that largely targets fluid-filled, atelectatic lungs. Clinicians should adapt their management plan to each patient, accounting for their individual characteristics, as well as their preferences and values—the advice is not a one-size-fits-all approach.

In the midst of a pandemic, we can serve our patients best by organising and participating in collaborative research programmes to facilitate learning while caring for patients, to better inform the management of critically ill patients with COVID-19. Particularly in this era of social media, we need to balance anecdotes and case reports with the scientific rigour needed to support any necessary shifts in the current paradigm of patient management. Until such new data emerge, we should continue to manage patients with ARDS from COVID-19 pneumonia with our current evidence-based practices, informed by bedside physiology.

Contributors

EF and DB conceived the manuscript. EF conducted the search and drafted the manuscript. All authors critically revised the manuscript and accepted the final version for publication.

Declaration of interests

EF is supported by a New Investigator Award from the Canadian Institutes of Health Research, and receives personal fees from Alung Technologies, Fresenius Medical Care, and MCI Cardiopulmonary, all outside of the submitted work. JRB receives grants from the US National Institutes of Health (R22-HL133469, R22-HL143506), and reports personal fees from Hamilton Medical and Sedana Medical, outside of the submitted work. LB’s laboratory has received research grants and equipment from Medtronic Covidien, Fisher Paykel, Air Liquide, Philips, and Sentec; and has a patent with General Electric. CSC is supported through grants from the National Institutes of Health (HL140026); she also receives research support from Roche and Genentech and has previously received research support from Bayer; she reports personal fees from Quark and GenLe, outside of the submitted work. NDF reports personal fees from Getinge and Xenios, outside of the

Search strategy and selection criteria

We searched PubMed for articles published in English between Jan 1, 1950, and June 8, 2020, using combinations of the terms “coronavirus”, “COVID-19”, “SARS-CoV-2”, “nCoV”, “acute respiratory distress syndrome”, “mechanical ventilation”, “critical care”, and “intensive care”. We determined which articles were relevant on the basis of the article’s title and citations. We also found articles through searches of the authors’ personal files and reviewed relevant references cited in retrieved articles. The final reference list was generated on the basis of relevance to the topics covered in this Viewpoint.
submitted work. ASS reports personal fees from Baxter and Novalung/ Xenios, outside of the submitted work. DB receives research support from ALung Technologies and was previously on their medical advisory board; he has been on medical advisory boards for Baxter, BREETHE, Xenios, and Hemovent.

References
1 Pan C, Chen L, Lu C, et al. Lung recruitability in SARS-CoV-2 associated acute respiratory distress syndrome: a single-center, observational study. Am J Respir Crit Care Med 2020; 201: 1294–97.
2 Zuehr DR, Allalina J, Petri CR, et al. Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study. Am J Respir Crit Care Med 2020; published online April 29. DOI:10.1164/rccm.202004-1163LE.
3 Bos LD, Paulus F, Visar AP, Beenen LFM, Schultz MJ. Subphenotyping ARDS in COVID-19 patients: consequences for ventilator management. Ann Am Thorac Soc 2020; published online May 12. DOI:10.1513/AnnalsATS.202004-3769RL.
4 Schenck EJ, Hoffman K, Goyal P, et al. Respiratory mechanics and gas exchange in COVID-19 associated respiratory failure. Ann Am Thorac Soc 2020; published online May 20. DOI:10.1513/AnnalsATS.202005-4279RL.
5 Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020; 395: 1763–70.
6 Haudebourg A-F, Perier P, Tuffet S, et al. Respiratory mechanics of COVID-19 vs non-COVID-19 associated acute respiratory distress syndrome. Am J Respir Crit Care Med 2020; published online June 1. DOI:10.1164/rccm.202004-1216LE.
7 Fan E, Brodie D, Slutsky AS. Acute respiratory distress syndrome: advances in diagnosis and treatment. JAMA 2018; 319: 698–710.
8 Reddy K, Sinha P, O’Rane CM, et al. Subphenotypes in critical care: translation into clinical practice. Lancet Respir Med 2020; 8: 631–43.
9 Gattinoni L, Coppola S, Cressoni M, Busana M, Chiumello D. Covid-19 does not lead to a ‘typical’ acute respiratory distress syndrome. Am J Respir Crit Care Med 2020; published online March 30. DOI:10.1164/rccm.202003-0817LE.
10 Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med 2020; published online April 14. DOI:10.1007/s00134-020-06013-2.
11 Marinj JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA 2020; published online April 24. DOI:10.1001/jama.2020.6825.
12 Phua J, Weng L, Ling L, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med 2020; 8: 506–12.
13 Brochard L, Slutsky A, Pesenti A. Mechanical ventilation to minimize progression of lung injury in acute respiratory failure. Am J Respir Crit Care Med 2017; 195: 438–42.
14 Famous KR, Delucchi K, Ware LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 2017; 195: 331–38.
15 Calee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2014; 2: 611–20.
16 Chen L, Del Sorbo L, Greico DL, et al. Potential for lung recruitment estimated by the recruitment-to-inflation ratio in acute respiratory distress syndrome. A clinical trial. Am J Respir Crit Care Med 2020; 201: 178–87.
17 Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342: 1301–08.
18 Hager DN, Krishnan JA, Hayden DL, Brower RG, for the ARDS Clinical Trials Network. Tidal volume reduction in patients with acute lung injury when plateau pressures are not high. Am J Respir Crit Care Med 2005; 172: 1241–45.
19 Serpa Neto A, Cardoso SO, Manetta JA, et al. Association between use of lung protective ventilation with lower tidal volumes and clinical outcomes among patients with acute respiratory distress syndrome: a meta-analysis. JAMA 2012; 308: 1651–59.
20 Hoegel S, Burns N, Angulo M, et al. Capturing the multifactorial nature of ARDS—‘two-lifl’ approach to model murine acute lung injury. Physiol Rep 2018; 6:e13648.
21 Yoshida T, Fujino Y, Amato MPB, Kavangh BP. Fifty years of research in ARDS: spontaneous breathing during mechanical ventilation. Risks, Mechanisms, and Management. Am J Respir Crit Care Med 2017; 195: 983–92.
22 Lellouche F, Delorme M, Brochard L. Impact of respiratory rate and dead space in the current era of lung protective mechanical ventilation. Chest 2020; 158: 45–47.
23 Lyazzidi A, Thille AW, Cargettes G, Galia F, Brochard L, Richard J-CM. Bench test evaluation of volume delivered by modern ICU ventilators during volume-controlled ventilation. Intensive Care Med 2010; 36: 2074–80.
24 Morales-Quinteros L, Campbri-Rimbals M, Bringué J, Bos LD, Schultz MJ, Artigas A. The role of hypercapnia in acute respiratory failure. Intensive Care Med Exp 2019; 7: 39.
25 Nin N, Muriel A, Peruchas O, et al. Severe hypercapnia and outcome of mechanically ventilated patients with moderate or severe acute respiratory distress syndrome. Intensive Care Med 2017; 43: 200–08.
26 Delucchi K, Famous KR, Ware LB, et al. Stability of ARDS subphenotypes over time in two randomised controlled trials. Thorax 2018; 73: 439–45.
27 Wunsch H. Mechanical ventilation in COVID-19: interpreting the current epidemiology. Am J Respir Crit Care Med 2020; published online May 13. DOI:10.1164/rccm.202004-1185ED.
28 Briel M, Meade M, Mercart A, et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA 2020; 303: 862–73.
29 Suter PM, Fairley B, Isenberg MD. Optimum end-expiratory airway pressure in patients with acute pulmonary failure. N Engl J Med 1975; 292: 284–89.
30 Dantzer DR, Lynch JP, Weg JG. Depression of cardiac output is a mechanism of shunt reduction in the libarary of acute respiratory failure. Chest 1980; 77: 616–42.
31 ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012; 307: 1526–33.
32 Bellani G, Laffey JG, Pham T, et al. Epidemiology patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016; 315: 788–800.
33 Bhattacharya PK, Ghassemi-Mejri B, Nichols M, et al. Covid-19 in critically ill patients in the seattle region - case series. N Engl J Med 2020; published online March 30. DOI:10.1056/NEJMoaa2004500.
34 Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020; published online April 6. DOI:10.1001/jama.2020.5394.
35 Schaller T, Hirschhüki K, Burkhardt K, et al. Postmortem examination of patients with COVID-19. JAMA 2020; published online May 21. DOI:10.1001/jama.2020.8907.
36 Fan E, Del Soho L, Goligher EC, et al. An official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine clinical practice guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2017; 195: 1253–63.
37 Griffiths MJD, McCauley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res 2019; 6: e000420.
38 Papazian L, Aubron C, Brochard L, et al. Formal guidelines: management of acute respiratory distress syndrome. Intensive Care Med 2019; 45: 69–88.
39 Bellani G, Laffey JG, Pham T, et al. Noninvasive ventilation of patients with acute respiratory distress syndrome. Insights from the LUNG SAFE study. Am J Respir Crit Care Med 2017; 195: 67–77.
40 Tobin MJ. Basing respiratory management of coronavirus on physiological principles. Am J Respir Crit Care Med 2020; published online April 13. DOI:10.1164/rccm.202004-1076ED.
41 Tonelli R, Fantini R, Tabbi L, et al. Inspiratory effort assessment by esophageal manometry early predicts noninvasive ventilation outcome in de novo respiratory failure: a pilot study. Am J Respir Crit Care Med 2020; published online April 21. DOI:10.1164/rccm.201912-2312OC.
42 Amato MBP, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med 2015; 372: 747–55.

43 Sahetya SK, Goligher EC, Brower RG. Fifty years of research in ARDS. Setting positive end-expiratory pressure in acute respiratory distress syndrome. Am J Respir Crit Care Med 2017; 195: 1429–38.

44 Guerin C, Reignier J, Richard J-C, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 2013; 368: 2159–68.

45 Elharrar X, Trigui Y, Deis A-M, et al. Use of prone positioning in nonintubated patients with COVID-19 and hypoxemic acute respiratory failure. JAMA 2020; published online May 15. DOI:10.1001/jama.2020.8255.

46 Sartini C, Tresoldi M, ScarPELLini P, et al. Respiratory parameters in patients with COVID-19 after using noninvasive ventilation in the prone position outside the intensive care unit. JAMA 2020; published online May 15. DOI:10.1001/jama.2020.7861.

47 Coppo A, Bellani G, Winterton D, et al. Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study. Lancet Respir Med 2020; published online June 19. https://doi.org/10.1016/S2213-2600(20)30268-X.

48 Munshi L, Del Sorbo L, Adhikari NKJ, et al. Prone position for acute respiratory distress syndrome: A systematic review and meta-analysis. Ann Am Thorac Soc 2017; 14: S280–88.

49 Abrams D, Ferguson ND, Brochard L, et al. ECMO for ARDS: from salvage to standard of care? Lancet Respir Med 2019; 7: 108–10.

50 Wichmann D, Sperhake J-P, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 2020; published online May, 6. DOI:10.7326/M20-2003.

51 Angus DC. Optimizing the trade-off between learning and doing in a pandemic. JAMA 2020; published online March 30. DOI:10.1001/jama.2020.4984.

52 Singer BD, Jain M, Budinger GR, Wunderink RG. A call for rational intensive care in the era of COVID-19. Am J Respir Cell Mol Biol 2020; published online April, 21. DOI:10.1165/rcmb.2020–0151LE.

53 RochwerG B, Parke R, Murthy S, et al. Misinformation during the coronavirus disease 2019 Outbreak. Critical Care Explorations 2020; 2: e0098–96.

54 Cook DJ, Marshall JC, Fowler RA. Critical illness in patients with COVID-19: mounting an effective clinical and research response. JAMA 2020; published online April 6. DOI:10.1001/jama.2020.5775.

© 2020 Elsevier Ltd. All rights reserved.